{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:13:02Z","timestamp":1794305582986,"version":"4.9.0"},"reference-count":67,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background: Hidradenitis suppurativa (HS), also known as acne inversa or Verneuil\u2019s disease, is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicles characterized by inflammatory, painful, deep-rooted lesions in the areas of the body characterized by the presence of the apocrine glands. Unfortunately, huge unmet needs still remain for its treatment. Objective: The purpose of our review was collecting all cases, case series, trials, and ongoing studies available in the literature on the use of this class of drugs for HS. Materials and Methods: The investigated manuscripts included trials, reviews, letters to the editor, real-life studies, case series, and reports. Manuscripts were identified, screened, and extracted for the relevant data following the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines. Results: We selected 56 articles of which 25 met the selection criteria for our review. Among the JAK inhibitors to date, there is only one published clinical trial in the literature (Janus kinase 1 inhibitor INCB054707), a real-life study with 15 patients up to week 24 in which upadacitinib was used and a case series where tofacitinib was successfully used. Conversely, there are several ongoing clinical trials. Conclusions: Results to date in the literature show promising levels of efficacy and the safety of JAK inhibitors in HS. Several clinical trials are underway from which it will be very important to compare the available data. There are still too few studies conducted with a low sample size, so it remains critical to investigate this issue further in the future with a real-life study involving a large sample of patients in order to provide safe and viable therapeutic alternatives for HS.<\/jats:p>","DOI":"10.3390\/medicina59040801","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T04:53:59Z","timestamp":1681966439000},"page":"801","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2523-050X","authenticated-orcid":false,"given":"Fabrizio","family":"Martora","sequence":"first","affiliation":[{"name":"Section of Dermatology\u2014Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Scalvenzi","sequence":"additional","affiliation":[{"name":"Section of Dermatology\u2014Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4658-7391","authenticated-orcid":false,"given":"Angelo","family":"Ruggiero","sequence":"additional","affiliation":[{"name":"Section of Dermatology\u2014Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-0592","authenticated-orcid":false,"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[{"name":"Section of Dermatology\u2014Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Battista","sequence":"additional","affiliation":[{"name":"Section of Dermatology\u2014Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1803-2046","authenticated-orcid":false,"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[{"name":"Section of Dermatology\u2014Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"ref_1","first-page":"114","article-title":"What is hidradenitis suppurativa?","volume":"63","author":"Lee","year":"2017","journal-title":"Can. Fam. Phys."},{"key":"ref_2","first-page":"1017","article-title":"Hidradenitis Suppurativa: Review of the Pathogenesis and Treatment","volume":"15","author":"Kurayev","year":"2016","journal-title":"J. Drugs Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/ced.15291","article-title":"Strategies adopted in a southern Italian referral centre to reduce adalimumab discontinuation: Comment on \u2018Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?\u2019","volume":"47","author":"Martora","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.2017.16691","article-title":"Hidradenitis Suppurativa","volume":"318","author":"Saunte","year":"2017","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000521712","article-title":"A Case of Pemphigus Vulgaris and Hidradenitis Suppurativa: May Systemic Steroids Be Considered in the Standard Management of Hidradenitis Suppurativa?","volume":"8","author":"Martora","year":"2022","journal-title":"Ski. Appendage Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/bjd.19337","article-title":"Efficacy and safety of topical resorcinol 15% as long-term treatment of mild-to-moderate hidradenitis suppurativa: A valid alternative to clindamycin in the panorama of antibiotic resistance","volume":"183","author":"Molinelli","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jaad.2021.10.060","article-title":"Alexandrite laser as an adjuvant therapy in the management of mild to moderate hidradenitis suppurativa: A controlled prospective clinical study","volume":"87","author":"Molinelli","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2020.12.089","article-title":"The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study","volume":"85","author":"Tzellos","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjd.18983","article-title":"Evidence for a \u2018window of opportunity\u2019 in hidradenitis suppurativa treated with adalimumab: A retrospective, real-life multicentre cohort study","volume":"184","author":"Marzano","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Martora, F., Marasca, C., Picone, V., Fornaro, L., Megna, M., and Fabbrocini, G. (2023). How Adalimumab Impacts Antibiotic Prescriptions in Patients Affected by Hidradenitis Suppurativa: A 1-Year Prospective Study and Retrospective Analysis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12030837"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000477459","article-title":"Swiss Practice Recommendations for the Management of Hidradenitis Suppurativa\/Acne Inversa","volume":"233","author":"Hunger","year":"2017","journal-title":"Dermatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations","volume":"81","author":"Alikhan","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000503605","article-title":"A Comparison of International Management Guidelines for Hidradenitis Suppurativa","volume":"237","author":"Hendricks","year":"2021","journal-title":"Dermatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/CCID.S391356","article-title":"Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience","volume":"16","author":"Martora","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamadermatol.2021.4805","article-title":"Drug Survival of Biologics in Patients With Hidradenitis Suppurativa","volume":"158","author":"Ring","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): Week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Fukaura, R., and Akiyama, M. (2023). Targeting IL-36 in Inflammatory Skin Diseases. Biodrugs, 1\u201315.","DOI":"10.1007\/s40259-023-00587-5"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kimball, A.B., Prens, E.P., Passeron, T., Maverakis, E., Turchin, I., Beeck, S., Drogaris, L., Geng, Z., Zhan, T., and Messina, I. (2023). Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial. Dermatol. Ther., 1\u201313.","DOI":"10.1007\/s13555-023-00913-3"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention","volume":"66","author":"Schwartz","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/eji.201646680","article-title":"Targeting JAK\/STAT signalling in inflammatory skin diseases with small molecule inhibitors","volume":"47","author":"Welsch","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging Topical and Systemic JAK Inhibitors in Dermatology","volume":"10","author":"Solimani","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic re-views","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/bjd.20969","article-title":"Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: Results from two phase II studies","volume":"186","author":"Alavi","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s40265-021-01566-2","article-title":"Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa","volume":"81","author":"Aarts","year":"2021","journal-title":"Drugs"},{"key":"ref_28","unstructured":"European Medicines Agency (2021). Upadacitinib Summary of Product Characteristics, European Medicines Agency."},{"key":"ref_29","unstructured":"US Food and Drug Administration (2019). Upadacitinib Prescribing Information, US Food and Drug Administration."},{"key":"ref_30","unstructured":"RINVOQ (2021). Summary of Product Characteristics, AbbVie Deutschland GmbH & Co. KG."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e15346","DOI":"10.1111\/dth.15346","article-title":"Upadacitinib improved alopecia areata in a patient with atopic dermatitis: A case report","volume":"35","author":"Cantelli","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/jdv.18137","article-title":"Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: A real-life experience","volume":"36","author":"Napolitano","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jaad.2022.07.047","article-title":"Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study","volume":"87","author":"Kozera","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1111\/ced.15306","article-title":"Management of patients with hidradenitis suppurativa during COVID-19 vaccination: An experience from southern Italy. Comment on: \u2018Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa\u2019","volume":"47","author":"Martora","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_35","first-page":"e43","article-title":"Skin reaction after SARS-CoV-2 vaccines Reply to \u2018cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: A real-life multicentre experience\u2019","volume":"37","author":"Martora","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1111\/jdv.18302","article-title":"Reply to \u2018Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2\u2019 by Solimani et\u2009 al","volume":"36","author":"Martora","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1111\/ced.15336","article-title":"The impact of COVID-19 infection on patients with psoriasis treated with biologics: An Italian experience","volume":"47","author":"Ruggiero","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1001\/jamadermatol.2017.0001","article-title":"Treatment of Alopecia Areata With Tofacitinib","volume":"153","author":"Ibrahim","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/1744666X.2018.1512404","article-title":"Tofacitinib for the treatment of psoriasis and psoriatic arthritis","volume":"14","author":"Berekmeri","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.alit.2021.10.004","article-title":"Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors","volume":"71","author":"Nakashima","year":"2021","journal-title":"Allergol. Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: A phase II a randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Napolitano, M., Fabbrocini, G., Martora, F., Picone, V., Morelli, P., and Patruno, C. (2021). Role of Aryl Hydrocarbon Receptor Activation in Inflammatory Chronic Skin Diseases. Cells, 10.","DOI":"10.3390\/cells10123559"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1111\/jdv.18263","article-title":"The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis\u2014A network meta-analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_46","unstructured":"(2020, July 31). Tofacitinib for Immune Skin Conditions in Down Syndrome (NCT04246372), Available online: https:\/\/www.clinicaltrials.gov\/."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jdcr.2019.10.010","article-title":"Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients","volume":"6","author":"Savage","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e14021","DOI":"10.1111\/dth.14021","article-title":"A case paradoxical hidradenitis suppurativa with janus kinase inhibitor, literature review and pooled analysis of biological agent-induced HS","volume":"33","author":"Shaharir","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Ruggiero, A., Martora, F., Picone, V., Marano, L., Fabbrocini, G., and Marasca, C. (2022). Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020455"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000506074","article-title":"Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-\u03b1 Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis","volume":"236","year":"2020","journal-title":"Dermatology"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Martora, F., Fabbrocini, G., Marasca, C., Battista, T., and Megna, M. (2023). Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on \u2018Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab\u2019. Clin. Exp. Dermatol., llad082.","DOI":"10.1093\/ced\/llad082"},{"key":"ref_52","unstructured":"Sanz, P.L., P\u00e9rez, M.G., Defez, J.M.A., Ram\u00edrez, C.G., C\u00f3rdoba, S.M., and Mart\u00ednez, M.E.A. (2023). Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab. Clin. Exp. Dermatol., llad003."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/09546634.2015.1094179","article-title":"Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa","volume":"27","author":"Delobeau","year":"2015","journal-title":"J. Dermatol. Treat."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"459","DOI":"10.23736\/S0392-0488.18.05875-3","article-title":"Hidradenitis suppurativa\/acne inversa: A prospective bacteriological study and review of the literature","volume":"155","author":"Benzecry","year":"2020","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1365-2133.2006.07155.x","article-title":"Clindamycin and rifampicin combination therapy for hidradenitis suppurativa","volume":"154","author":"Griffiths","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.det.2015.08.013","article-title":"Antibiotic Treatment of Hidradenitis Suppurativa","volume":"34","author":"Bettoli","year":"2016","journal-title":"Dermatol. Clin."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.5114\/ada.2022.115323","article-title":"Surgical management of hidradenitis suppurativa","volume":"39","author":"Gierek","year":"2022","journal-title":"Adv. Dermatol. Allergol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Gierek, M., \u0141abu\u015b, W., S\u0142abo\u0144, A., Zi\u00f3\u0142kowska, K., Ocha\u0142a-Gierek, G., Kitala, D., Szyluk, K., and Niemiec, P. (2022). Co-Graft of Acellular Dermal Matrix and Split Thickness Skin Graft\u2014A New Reconstructive Surgical Method in the Treatment of Hidradenitis Suppurativa. Bioengineering, 9.","DOI":"10.3390\/bioengineering9080389"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.jid.2016.04.036","article-title":"Intrinsic Defect in Keratinocyte Function Leads to Inflammation in Hidradenitis Suppurativa","volume":"136","author":"Hotz","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4049\/jimmunol.0903907","article-title":"Deficiency of IL-22 Contributes to a Chronic Inflammatory Disease: Pathogenetic Mechanisms in Acne Inversa","volume":"186","author":"Wolk","year":"2011","journal-title":"J. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2340\/00015555-3012","article-title":"Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II","volume":"98","author":"Kimball","year":"2018","journal-title":"Acta Derm.-Venereol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/bjd.14338","article-title":"Ustekinumab in hidradenitis suppurativa: Clinical results and a search for potential biomarkers in serum","volume":"174","author":"Blok","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-020-0082-8","article-title":"Kinase inhibition in autoimmunity and inflammation","volume":"20","author":"Zarrin","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1126\/science.1071545","article-title":"A Road Map for Those Who Don\u2019t Know JAK-STAT","volume":"296","author":"Aaronson","year":"2002","journal-title":"Science"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/exd.14338","article-title":"Target molecules for future hidradenitis suppurativa treatment","volume":"30","author":"Zouboulis","year":"2021","journal-title":"Exp. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40271-022-00614-7","article-title":"Patient Preferences in the Management of Hidradenitis Suppurativa: Results of a Multinational Discrete Choice Experiment in Europe","volume":"16","author":"Willems","year":"2023","journal-title":"Patient"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Hoffman, L.K., Tomalin, L.E., Schultz, G., Howell, M.D., Anandasabapathy, N., Alavi, A., Su\u00e1rez-Fari\u00f1as, M., and Lowes, M.A. (2018). Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0203672"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/4\/801\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:19:34Z","timestamp":1760123974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/4\/801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":67,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["medicina59040801"],"URL":"https:\/\/doi.org\/10.3390\/medicina59040801","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]}}}